Shining a light on the nervous system to thwart disease
(Case Western Reserve University) Researchers from Case Western Reserve University School of Medicine, Vanderbilt University, and University of Pittsburgh have received a four-year, $9 million grant from the National Institutes of Health to develop enhanced infrared light technology (infrared neuromodulation) for potentially treating a variety of diseases, including cardiac arrhythmias, high and low blood pressure, asthma, sleep apnea and diarrhea, one of the leading killers of children worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news
URMC Cardiologist Receives High Honor from American Heart Association
University of Rochester Medical Center cardiologist Arthur J. Moss, M.D., whose research on cardiac arrhythmias has saved countless lives and changed the treatment of heart disease worldwide, was honored with the 2017 James B. Herrick Award at the American Heart Association ’s Scientific Sessions. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.
THE CONFIRM RX ICM COMBINES ADVANCED MEDICAL DEVICE WITH THE LATEST IN MOBILE AND DIGITAL TECHNOLOGY
PHYSICIANS CAN REMOTELY MONITOR THEIR PATIENTS WITH CONFIRM RX FOR EVEN THE MOST DIFFICULT TO DETECT CARDIAC ARRHYTHMIAS, INCLUDING IRREGULAR HEARTBEATS... Devices, Monitoring, Cardiology, FDA, Product Launch Abbott, Confirm Rx, Insertable Cardiac Monitor, Cardiac Monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2017 Category: Pharmaceuticals Source Type: news
Abbott wins FDA nod for Confirm Rx smartphone-connected cardiac monitor
Abbott (NYSE:ABT) said today it won FDA clearance for its Confirm Rx insertable cardiac monitor, touting it as the 1st and only smartphone compatible ICM designed to help identify cardiac arrhythmias.
The Confirm Rx system includes a sensor designed to be implanted just under the skin over the chest in a minimally-invasive outpatient procedure, the company said.
The newly cleared device features incorporated Bluetooth wireless technology to allow patients to connect to the device on their smartphone devices through Abbott’s myMerlin mobile application. Data collected by the device is also transmitted to the patient...
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Patient Monitoring Regulatory/Compliance Abbott Source Type: news
Getting to the heart of mapping arrhythmia-related excitations
(American Institute of Physics) Atrial fibrillation is the most prevalent form of cardiac arrhythmia, affecting up to 6 million people in the US alone. Common treatments for severe forms of the erratic beating phenomenon are controversial, and guided by detection methods that are not yet standardized or fully refined. But research from a group of cross-disciplinary scientists, published this week in the journal Chaos, offers a computational approach to understanding the important factors involved in measuring cardiac excitation waves. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2017 Category: International Medicine & Public Health Source Type: news
Abbott Catches Up to Peers With MRI-Compatible ICD
Abbott Laboratories acquired St. Jude Medical earlier this year knowing that the company trailed behind its peers in the cardiac rhythm management (CRM) space by not having a MRI-compatible pacemaker or implantable cardioverter defibrillator (ICD) system. It seems Abbott has officially caught up in that category though, first with FDA approval of the Assurity MRI pacemaker and the Tendril MRI pacing lead during the first quarter, and now with FDA approval of MRI-conditional labeling for the Ellipse ICD system.
Abbott said the recent approval covers one of its most widely-used ICD systems and associated high voltage leads. ...
Source: MDDI - September 23, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: MD & M Minneapolis Labeling Business Source Type: news
Abbott wins MR-conditional label for Ellipse ICDs
Abbott (NYSE:ABT) said today that it won an MR-conditional label from the FDA for the Ellipse implantable cardioverter defibrillator it acquired along with St. Jude Medical early this year.
The MR-conditional label applies to Ellipse and the Tendril MRI pacing lead and the Durata and Optisure high-voltage leads, the Chicago-area medical device giant said.
“When you consider the number of patients each year who rely on the lifesaving treatment delivered by an ICD device, it is critical to continually innovate to provide new benefits to people battling complex arrhythmias and other cardiac conditions,” cardiac ar...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Food & Drug Administration (FDA) Imaging Regulatory/Compliance Abbott Cardiac Rhythm Management Source Type: news
Is BioSig for Real This Time With Its Pure EP?
A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation.
The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atrial fi...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nancy Crotti Tags: MD & M Minneapolis R Software Source Type: news
Abbott wins FDA nod for HeartMate 3 pump
Abbott (NYSE:ABT) said today that the FDA approved its HeartMate 3 implantable pump for heart failure patients awaiting a transplant.
The approval is the latest for the HeartMate line of left ventricular assist devices first developed by Thoratec, which was later acquired by St. Jude Medical before a $25 billion merger brought it to Abbott earlier this year.
Abbott said HeartMate 3 features full magnetic levitation for the pump’s impeller, aiming to cause less trauma to blood cells as they pass through the pump. Although it is smaller than its predecessor, Abbott claimed it has the industry’s largest “p...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices Food & Drug Administration (FDA) Abbott Source Type: news
Numerate receives NIH funding to discover new anti-arrhythmic treatments
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded a small business innovation research (SBIR) Phase I grant to Numerate to boost a new drug programme for cardiac arrhythmias. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news
Not all astrocytes in the brain are the same, study finds
From afar, the billions of stars in our galaxy look indistinguishable, just as the billions of star-shaped astrocytes in our brains appear the same as each other. But UCLA researchers have now revealed that astrocytes, a type of brain cell that supports and protects neurons, aren ’t all the same. While stars might be categorized by their size, age and heat, the supportive brain cells vary when it comes to shape, molecular machinery and functioning.The findings,published today in the journal Neuron, should make it easier for researchers to study how astrocytes relate to disease, or to develop drugs that aim to target s...
Source: UCLA Newsroom: Health Sciences - July 13, 2017 Category: Universities & Medical Training Source Type: news
CathVision inks investment deal for electrophysiology system
Early-stage medical device company CathVision said today it inked a “multi-million venture investment” to support the development and marketing of its electrophysiology recording system designed for treating cardiac arrhythmia.
The undisclosed investment came from Scandanavian-based VF Venture and Borean Innovation, Denmark-based CathVision said.
“CathVision works in one of the fastest growing segments in medical technology. CathVision’s team has worked patiently and consistently with their product over a number of years, and we have followed the company for several years. I think CathVision represe...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular cathvision Source Type: news
Adverse Drug Event Causality Analysis (ADECA): a process for evaluating evidence and assigning drugs to risk categories for sudden death - Woosley RL, Romero K, Heise CW, Gallo T, Tate J, Woosley RD, Ward S.
Growing evidence indicates that many drugs have the ability to cause a potentially lethal cardiac arrhythmia, torsades de pointes (TdP). This necessitates the development of a compilation of drugs that have this potential toxicity. Such a list is helpful i... (Source: SafetyLit)
Source: SafetyLit - June 24, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Tenth year of data on cardiac arrhythmia treatment launched at European congress
(European Society of Cardiology) The tenth year of data on cardiac arrhythmia treatment is being launched at EHRA EUROPACE - CARDIOSTIM 2017. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2017 Category: International Medicine & Public Health Source Type: news
Medical News Today: Does the sound of airplanes raise blood pressure risk?
A new study investigates the effect of long-term exposure to aircraft noise on the risk of high blood pressure, cardiac arrhythmia, and stroke. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2017 Category: Consumer Health News Tags: Public Health Source Type: news
